In vitro analysis shows SIRT1 aptamer reduces inflammatory markers in RAW 264.7 cells, implying potential therapeutic benefits.
Background: Inflammation serves as the bedrock for a diverse range of physiological and pathological processes. Para-inflammation is the adaptive response that occurs when tissue stress or dysfunction occurs. SIRT1 is a sirtuin family member. Numerous biological processes, such as cellular senescence, apoptosis, oxidative stress and inflammation are significantly influenced by SIRT1-mediated deacetylation. Aim: The objective of this study is to assess the anti-inflammatory properties of Sirtuin1 activator (SIRT1 aptamer) by employing RAW 264.7 macrophage cell lines via the inhibitory effect of it on tumor necrosis factor-α, interleukin-1β and interleukin-6. Methods: Variable concentrations of SIRT1 aptamer were applied to cells. The viability of the RAW 264.7 cell line was examined for the cytotoxic effects of SIRT1 aptamer using tetrazolium bromide (MTT) assay. After seeding RAW 264.7 cells. The cells starved and pretreated with aptamer at concentration 1.98 µM,4 µM for 1hr, after those cells were exposed to LPS (10 μg/ml), Harvesting of the RAW 264.7 cell culture supernatants. In accordance with the manufacturer's guidelines, the concentrations of TNF- α., IL-1β and IL-6 were ascertained utilizing enzyme-linked immunosorbent assay kits. Results: The half–maximal inhibitory concentration for SIRT1 aptamer was 1.98 µM. At concentrations 1.98 µM,4 µM of its the level of tumor necrosis factor-α was decreased significantly by (P<0.05, <0.005, respectively) compared to the group treated with LPS alone, the SIRT1 aptamer at concentrations of 1.9 µM and 4 µM effectively suppresses LPS-induced cellular inflammation (level of Interleukin-6) in the RAW264.7 cell line. This effect is considerably different from the group treated with LPS alone (P<0.05 and <0.001, respectively). there was a significant decrease in LPS-induced cellular inflammation in RAW 264.7 cells when SIRT1 aptamer was added to the LPS stimulated cells, as compared to the (LPS-only) positive control p <0.001. Conclusions: The use of SIRT1 aptamer exhibited superior anti-inflammatory properties by a reduction in the generation of pro-inflammatory mediators TNF-α, IL-6 and (IL)-1β from RAW264.7 cells that were activated with LPS. This can result in its utilization as a highly promising biotherapy with notable anti-inflammatory characteristics.
No takes yet. Share an insight, caveat, or question.
Nahi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: